Expressing concern over a rise in black fungus or Mucormycosis cases in the country, Congress leader Rahul Gandhi on Tuesday again targeted the central government on its efforts to curb the rise in fungal infection.
Taking to Twitter, he sought answers from the Centre to three of his questions.
"Central Government should clarify about the Black fungus epidemic - 1. What is being done for Amphotericin B drug shortage? 2. What is the procedure for getting this medicine to the patient? 3. Instead of giving treatment, why is the public getting bogged down in formalities by the government?" he posted on his Twitter page.
The Congress MP has previously also attacked the BJP government and blamed the "inefficiency" of the PM Narendra Modi government for the "epidemic of black fungus along with the Covid pandemic" in the country.
Cases of Covid-19 triggered black fungus across the country have witnessed a significant increase, which has also led to a significant rise in the death toll. Karnataka has reported 1,250 cases and 39 related deaths so far. In Madhya Pradesh's Indore city, 39 people died due to the infection. On Friday, two succumbed to the infection in Shimla, Himachal Pradesh. Uttar Pradesh's Meerut reported 147 black fungus cases in total.
Meanwhile, on Sunday, India received a consignment of 200,000 AmBisome (Amphotericin B injection), informed Ambassador of India to the United States, Taranjit Singh Sandhu.
(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
)